长春高新GS3-007a干混悬剂临床试验申请获得受理

Core Viewpoint - Changchun Gaoxin announced that its subsidiary, Changchun Jinsai Pharmaceutical, received the acceptance notice from the National Medical Products Administration for the clinical trial application of GS3-007a [1] Group 1: Company Developments - Changchun Jinsai Pharmaceutical's GS3-007a is an orally administered small molecule growth hormone secretagogue developed independently by the company [1] - The drug is classified as a Class 1 chemical drug and is intended for the treatment of pediatric growth hormone deficiency (PGHD) caused by endogenous growth hormone deficiency [1]